28 April 2022 - - US-based biotechnology company IgGenix, Inc will be moving to Lilly Gateway Labs, a shared innovation laboratory in South San Francisco, California, the company said.

In 2019, Eli Lilly and Co. (NYSE: LLY) announced the first Lilly Gateway Lab to speed the discovery of innovative medicines through collaboration with local biotech companies.

IgGenix joins 8 other leading biotechnology companies in the South San Francisco Gateway Labs.

More than 50m Americans have suffered from various types of allergies, the sixth leading cause of chronic illness in the United States.

IgGenix is driven to develop safer therapeutic options through its single-cell discovery platform, leveraging evolutionary biology designed to target monoclonal antibodies.

IgGenix is a privately held biotechnology company taking a revolutionary approach to directly alleviate food and other severe allergies by reengineering key antibodies involved in the allergic cascade.

Founded based on research by Stephen Quake, Kari Nadeau, and Derek Croote of a novel discovery platform developed at Stanford University, IgGenix isolates rare allergen-specific IgE antibodies responsible for allergic reactions and transforms them into IgG antibodies.

These therapeutic IgG antibodies are designed to alleviate and possibly prevent life-threatening allergic reactions, saving lives and reducing the constant fear that affects people living with severe allergies.

Lilly Gateway labs, Eli Lilly and company's first shared innovation lab designed to speed the discovery of innovative medicines, offers companies potential access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise.

With over 65,000 square feet of space, Lilly Gateway Lab has been designed with private lab modules and open areas for collaboration.

Companies who work in Lilly Gateway Labs have the potential to collaborate with Lilly on projects of mutual interest, participate in shared learning forums with Lilly experts and partners, and have the potential for financial investment from Lilly and their venture network.